Literature DB >> 5529716

The proteolytic action of Arvin on human fibrinogen.

M R Ewart, M W Hatton, J M Basford, K S Dodgson.   

Abstract

1. Human fibrinogen was subjected to proteolysis by enzyme preparations (clinical Arvin and IRC-50 Arvin) from the venom of Agkistrodon rhodostoma. 2. IRC-50 Arvin releases three peptides from fibrinogen, and these were identified as fibrinopeptides AP, AY and A. 3. The less purified ;clinical' Arvin releases, in addition to fibrinopeptides AP, AY and A, small amounts of two heptapeptides derived from fibrinopeptides AP and A, probably because it contains another enzyme as well as Arvin. 4. No fibrinopeptide B is released by either Arvin preparation. 5. Thus, although Arvin is known to differ from ;reptilase' from Bothrops jararaca in that it does not activate the enzyme that cross-links fibrin (fibrin-stabilizing factor), it is identical with reptilase with respect to the peptides that it liberates from fibrinogen.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5529716      PMCID: PMC1179257          DOI: 10.1042/bj1180603

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  15 in total

1.  Peptides obtained by tryptic hydrolysis of performic acid-oxidized ribonuclease.

Authors:  C H HIRS; S MOORE; W H STEIN
Journal:  J Biol Chem       Date:  1956-04       Impact factor: 5.157

2.  The chromatographic identification of some biologically important phosphate esters.

Authors:  R S BANDURSKI; B AXELROD
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  The effect of proteolytic enzymes on fibrin stabilizing factor.

Authors:  M Kopeć; Z S Latallo; M Stahl; Z Wegrzynowicz
Journal:  Biochim Biophys Acta       Date:  1969-07-01

4.  A simple method for preparing fibrinogen.

Authors:  W Straughn; R H Wagner
Journal:  Thromb Diath Haemorrh       Date:  1966-07-31

5.  Anticoagulant therapy with a purified fraction of Malayan pit viper venom.

Authors:  A A Sharp; B A Warren; A M Paxton; M J Allington
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

6.  Therapeutic defibrination in the treatment of thrombotic disease.

Authors:  W R Bell; W R Pitney; J F Goodwin
Journal:  Lancet       Date:  1968-03-09       Impact factor: 79.321

7.  Characterization of peptides released from human fibrinogen by Arvin.

Authors:  W H Holleman; L J Coen
Journal:  Biochim Biophys Acta       Date:  1970-03-31

8.  The action of Arvin on Fibrin Stabilizing Factor (factor 13).

Authors:  G H Barlow; W H Holleman; L Lorand
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1970-01

9.  The isolation and properties of the thrombin-like activity from Ancistrodon rhodostoma venom.

Authors:  M P Esnouf; G W Tunnah
Journal:  Br J Haematol       Date:  1967-07       Impact factor: 6.998

10.  The fibrinogen molecule: its size, shape, and mode of polymerization.

Authors:  C E HALL; H S SLAYTER
Journal:  J Biophys Biochem Cytol       Date:  1959-01-25
View more
  11 in total

1.  In vivo defibrination results in markedly decreased amounts of fibrinogen in rat megakaryocytes and platelets.

Authors:  P J Handagama; M A Shuman; D F Bainton
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

2.  Clotting and fibrinolysis.

Authors:  C R Prentice
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1975

3.  Mechanism of ancrod anticoagulation. A direct proteolytic effect on fibrin.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Clin Invest       Date:  1972-11       Impact factor: 14.808

4.  Studies on the coagulant enzyme from Agkistrodon rhodostoma venom. Isolation and some properties of the enzyme.

Authors:  M W Hatton
Journal:  Biochem J       Date:  1973-04       Impact factor: 3.857

5.  Some catalytic properties of IRC-50 Arvin.

Authors:  J P Collins; J M Basford; J G Jones
Journal:  Biochem J       Date:  1971-12       Impact factor: 3.857

Review 6.  Antithrombotic drugs: part II.

Authors:  A S Gallus; J Hirsh
Journal:  Drugs       Date:  1976       Impact factor: 9.546

Review 7.  Defibrinogenating enzymes.

Authors:  W R Bell
Journal:  Drugs       Date:  1997       Impact factor: 9.546

8.  Pharmacological and genetic depletion of fibrinogen protects from kidney fibrosis.

Authors:  Florin L Craciun; Amrendra K Ajay; Dana Hoffmann; Janani Saikumar; Steven L Fabian; Vanesa Bijol; Benjamin D Humphreys; Vishal S Vaidya
Journal:  Am J Physiol Renal Physiol       Date:  2014-07-09

9.  Fibrinogen Cleveland II. An abnormal fibrinogen with defective release of fibrinopeptide A.

Authors:  E D Crum; J R Shainoff; R C Graham; O D Ratnoff
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

10.  Molecular cloning and sequence analysis of the cDNA for ancrod, a thrombin-like enzyme from the venom of Calloselasma rhodostoma.

Authors:  L C Au; S B Lin; J S Chou; G W Teh; K J Chang; C M Shih
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.